Hybridoma clones, monoclonal antibodies, and methods of use

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9738717
SERIAL NO

14890317

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention is directed to a monoclonal antibody that recognizes human CD63 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and to methods of diagnosing and treating cancer and purifying exosomes using the antibody. The invention is further directed to pharmaceutical compositions comprising an antibody of the invention and a pharmaceutically acceptable carrier.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE445 N FIFTH STREET SUITE 600 PHOENIX AS 85004

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Azorsa, David Phoenix, US 8 17

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 22, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 22, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00